Search

A recent study on hypertrophic cardiomyopathy (HCM) has been published, tracing the discovery of this condition back to 1958. The research highlights the initial confusion surrounding HCM and its classification as a heart muscle disease. It also discusses the identification of genetic mutations associated with HCM and the potential for different phenotypes within affected families. The study emphasizes the importance of detecting ischemic scars and their role in increasing the risk of sudden death in HCM patients. [Extracted from the article]

A new study from Oita University in Japan has reported findings on the remission of cardiac sarcoidosis after the administration of methotrexate as a first-line drug therapy. The study involved a 54-year-old woman who developed new-onset heart failure and was diagnosed with cardiac sarcoidosis. The patient refused oral steroids and instead chose methotrexate as an alternative first-line drug. After nine months of oral therapy, the patient experienced remission of sarcoidosis, disappearance of heart failure symptoms, improved cardiac contractility, and a reduced frequency of ventricular arrhythmias. This research has been peer-reviewed and provides valuable insights into potential treatment options for cardiac sarcoidosis. [Extracted from the article]

A recent study conducted at the University Hospital Centre Rijeka in Croatia has examined the relationship between fentanyl use and sudden deaths. The research found that fentanyl, a synthetic opioid, is frequently involved in sudden deaths, and its use is increasing. The study also explored the role of a gene called KCNH2 in abnormal heart rhythms and sudden deaths related to fentanyl use. The researchers suggest that genetic testing and counseling could be beneficial for victims and their families. For more information, the full article can be accessed for free at the Diagnostics journal website. [Extracted from the article]

A study conducted at the Federal University Ceara in Fortaleza, Brazil, examined the use of implantable cardioverter-defibrillators (ICDs) in patients with chronic Chagas heart disease (CCHD). The study found that patients with secondary prevention and an ejection fraction less than 30% were more likely to receive appropriate therapies from the ICD. Additionally, patients with congestive heart failure, elevated functional class, and age over 75 years had higher mortality rates. The study highlights the importance of ICDs in managing CCHD and identifies predictors of mortality and appropriate device therapy in this population. [Extracted from the article]

A recent report from Washington University discusses research on heart arrest and the development of non-invasive optical heart pacing methods. The researchers created a double-transgenic fruit fly model suitable for optogenetic pacing, using excitatory and inhibitory opsin transgenes expressed in the fly heart. They were able to achieve non-invasive bi-directional heart pacing in Drosophila larvae and pupae using an integrated light stimulation and optical coherence microscopy system. This research provides valuable insights into cardiovascular research and may have implications for the development of new treatments for heart disorders and diseases. [Extracted from the article]

A study conducted by the University of Arizona Sarver Heart Center examined the association between reported physical symptoms and suspected hypertrophic cardiomyopathy (HCM). The study found that the presence of physical symptoms, such as chest pain, palpitations, shortness of breath, lightheadedness, ankle swelling, and dizziness, was not associated with a higher prevalence of HCM in participants undergoing screening echocardiography. The research suggests that the echocardiographic presence of suspected HCM does not necessarily correlate with the presence of physical symptoms. This information may be useful for individuals undergoing screening for HCM. [Extracted from the article]

The article from the Department of Internal Medicine explores new perspectives on managing hypertrophic cardiomyopathy (HCM) with exercise rehabilitation, challenging previous cautions against physical activity. Topics include the benefits of structured exercise on functional ability and psychological health, the positive impact on myocardial remodeling and cardiovascular fitness, and the complexities of implementing individualized rehabilitation programs.

A recent study conducted by researchers at the University of Glasgow in the United Kingdom examined the rates of sudden death after acute myocardial infarction (AMI). The study analyzed data from two clinical trials, the Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) and Valsartan in Acute Myocardial Infarction (VALIANT) trials. The findings revealed that the risk of sudden death or resuscitated cardiac arrest (RCA) was highest in the first month after AMI and declined rapidly thereafter. The study also showed that the rate of sudden death/RCA in patients with reduced left ventricular ejection fraction and/or pulmonary congestion has decreased compared to 20 years ago. The researchers concluded that interventions are needed to further protect individuals in the highest-risk period after an infarction. [Extracted from the article]

A patent has been issued to ZOLL Medical Corporation for a device that administers tests and adapts interactions for patients with cardiac conditions. The device, which can be worn on the torso, includes monitoring circuitry and a controller that receives input from the patient and adjusts the device's interaction mode accordingly. The device can deliver electrical therapeutic shocks and prompts the patient to perform specific actions in response. The patent describes different technology comfort modes and the ability to modify the patient interaction mode based on the patient's input. [Extracted from the article]

Researchers at the State University of New York (SUNY) Upstate Medical University have released new data on neurocardiac pathologies associated with potassium channelopathies. Voltage-gated potassium channels are expressed throughout the human body and are essential for physiological functions. Abnormalities in their function can lead to cardiac and neuronal pathologies, including seizures and sudden death. The study examines the expression patterns and electrical function of these channels in the brain and heart, and suggests that Kv7 channel modulators could provide a potential anti-seizure therapy for people with intractable epilepsy. The research aims to develop innovative and effective therapies for individuals at a high risk of sudden death. [Extracted from the article]

Inventors Gary A. Freeman, Thomas E. Kaib, and Jason T. Whiting have filed a patent application for a mobile monitoring and patient management system. The system allows users to customize the presentation of physiological information received from therapeutic and monitoring medical devices. It includes communication circuitry, a communications network, and a computing device with a user interface. Users can specify alerts, delegate access to information, and selectively display physiological information based on their preferences. The system can receive electrocardiogram data and information about treatments provided to patients, and it generates patient reports based on processed physiological information. [Extracted from the article]

A study conducted by researchers at Hassan II University of Casablanca explores the relationship between occupational exposure to anesthetic gases and the occurrence of tachyarrhythmia episodes in individuals with Wolff-Parkinson-White (WPW) syndrome. The case study focuses on a 39-year-old nurse who experienced paroxysmal tachyarrhythmia after exposure to anesthetic gases in the workplace. The research suggests that occupational exposure to anesthetic gases may increase the risk of tachyarrhythmias in individuals with WPW syndrome, and recommends professional reclassification as a precautionary measure to mitigate the risk of sudden death. [Extracted from the article]

A recent report from Cathay General Hospital in Taipei, Taiwan highlights the importance of point-of-care ultrasound (POCUS) in diagnosing life-threatening left atrium (LA) thrombus. The report describes the case of a 72-year-old man who presented at the emergency department with out-of-hospital cardiac arrest. Through POCUS, the patient was diagnosed with LA thrombus and systemic thromboembolism affecting the brain, kidney, and lower limbs. Despite immediate emergency thrombectomy, the patient ultimately died. The research emphasizes the need for POCUS in patients with a history of structural heart disease, particularly those who have undergone valve replacement surgery, to identify and treat potentially fatal thromboembolism events promptly. [Extracted from the article]

A study conducted at University Hospital in Siena, Italy, explored the feasibility of using a wearable sensor device to monitor the vitals of patients with Rett syndrome, a rare neurodevelopmental disorder primarily affecting females. The study found that sleep is disturbed in individuals with Rett syndrome and that they experience autonomic nervous system dysfunction, exercise fatigue, and an increased risk of sudden death. The researchers discovered that heart rate and heart rate variability could serve as objective markers of fatigue, illness severity, and disease progression in Rett syndrome. This study highlights the potential for continuous non-invasive home monitoring to improve the understanding and management of Rett syndrome. [Extracted from the article]

A recent study conducted at Texas A&M University examined the relationship between Beuren syndrome (WBS) and sudden death risk. WBS is a rare genetic condition characterized by distinct facial features, intellectual disability, and aortic stenosis. The researchers found that individuals with WBS have increased heart rate fragmentation (HRF), which is associated with adverse cardiovascular events and death. The study also introduced a new metric called Significant Acute Rate Drop (SARD) that may help detect vagal activity. These findings suggest that HRF and SARD can improve the identification of individuals at high risk for sudden cardiac death in both the WBS population and broader populations. [Extracted from the article]

A recent study conducted by researchers at the Department of Cardiology examined the relationship between genotype status and clinical outcome in hypertrophic cardiomyopathy (HCM). The study analyzed a large international cohort of HCM patients and found that genotype status (positive or negative) was not a predictor of clinical course, including mortality, heart failure progression, or sudden death. The researchers concluded that genotype status should not be used to dictate clinical management or predict outcomes in HCM. This study provides valuable insights into the genetic basis of HCM and its clinical implications. [Extracted from the article]

A researcher at Copenhagen University Hospital has emphasized the importance of conducting autopsies on cases of sudden cardiac death (SCD), particularly among young individuals, in order to diagnose inherited heart diseases and identify family members who may require cardiac evaluation. The researcher highlights that autopsy rates have been declining globally, leading to missed diagnoses and missed opportunities for treatment and prevention. The article calls for increased autopsy awareness and healthcare reform to reduce mortality from SCD. The research provides evidence on the role of autopsies in sudden death and suggests ways to integrate autopsy findings into clinical practice. [Extracted from the article]

A recent study conducted by researchers at China Pharmaceutical University explored the potential bioactive components in ginseng extract that could have a protective effect against myocardial damage. The study utilized various methods, including target cell extraction, spectrum-effect relationship analysis, and BP neural network classification, to identify the active substances in red ginseng extract. The researchers identified seven ginsenosides as the main active ingredients responsible for the cardiovascular activity of red ginseng. This research provides valuable insights for quality control in red ginseng products and offers ideas for screening active ingredients in traditional Chinese medicines. [Extracted from the article]

A recent study conducted at MGM Medical College in Indore, India, has reported on a case of sudden death due to spontaneous rupture of the right atrium in a patient with chronic lung disease. The 32-year-old man experienced symptoms of unease, giddiness, and unconsciousness before arriving at the hospital, where he was pronounced dead. Autopsy revealed an isolated right atrial rupture without any heart wall disease. The researchers suggest that chronic lung disease may have contributed to the increased intraluminal pressure in the heart chambers, leading to the rupture. The study emphasizes the importance of considering cardiac tamponade as a possibility in cases of sudden death, even without a history of trauma or myocardial infarction. [Extracted from the article]

A recent study conducted at Son Espases University Hospital in Palma de Mallorca, Spain, explored the possibility of screening for heart disease in children during routine check-ups at public health centers. The study involved collaboration between primary care pediatricians, nurses, and pediatric cardiologists, and collected data from 641 patients. The results showed that 30 patients had electrocardiographic alterations compatible with a risk of sudden cardiac death (SCD), but only 9 of them had been examined by a pediatric cardiologist. The study concluded that primary care pediatricians could potentially perform screenings for SCD risk in children, but further training in reading and interpreting pediatric electrocardiograms is necessary. [Extracted from the article]

A patent has been issued to ZOLL Medical Corporation for a mobile monitoring and patient management system. The system includes communications circuitry to receive physiological information from therapeutic and monitoring medical devices, as well as a computing device with a user interface to display the information. The therapeutic medical devices can include defibrillators, cardiac pacing devices, and portable ventilators, while the monitoring medical devices can include mobile cardiac monitoring devices, patient weight monitors, and blood pressure monitors. The system allows for customized patient reports based on user selection and access level, and can compile reports using physiological data such as heart rate, ECG data, and patient symptom data. [Extracted from the article]

A clinical trial, NCT06294028, is being conducted to compare the effectiveness of radiofrequency ablation and implantable defibrillators in patients with well-tolerated ventricular tachycardia and preserved left ventricular ejection fraction. Previous trials have not included this specific patient population, and sudden death rates are relatively low in this group. Retrospective data suggests that ablation of ventricular tachycardia may reduce mortality and recurrences. The trial will monitor for serious events over a 36-month follow-up period, including death, hospitalization, and emergency consultations related to ventricular arrhythmia or its treatment. Another clinical research study is also being conducted to compare the effectiveness and cost of two treatments for patients with ischemic heart disease and a history of infarction. The study will enroll 268 participants and is expected to be completed by December 31, 2029. The two treatment options being compared are implantation of an automatic defibrillator and percutaneous catheter ablation. The study will collect data on adverse events, quality of life, and medical-economic evaluation. Eligibility criteria include having a left ventricular ejection fraction greater than 35% and sustained monomorphic ventricular tachycardia. The study is being conducted by the University Hospital in Toulouse. [Extracted from the article]

Spacecraft Seven LLC has been issued a patent for a gene therapy using an adeno-associated virus (AAV) vector to treat arrhythmogenic right ventricular cardiomyopathy (ARVC), a form of adult-onset heart disease. ARVC is characterized by the breakdown of the muscular wall of the heart over time, leading to an increased risk of abnormal heartbeat and sudden death. The therapy involves administering a recombinant AAV vector containing a polynucleotide sequence encoding the Plakophilin-2 (PKP2) gene, which is associated with ARVC. The vector is administered intravenously, intracoronarily, intracardially, or through cardiac catheterization. The patent provides a potential treatment option for PKP2-related diseases and disorders, addressing an unmet need in the field. [Extracted from the article]

A recent study conducted at Government Medical College in Kerala, India, has published findings on endocardial fibroelastosis, a condition characterized by the thickening of the endocardium due to the proliferation of elastic and collagenous fibers. The study examined the case of a four-and-a-half-month-old baby who presented with seizures and subsequently developed heart failure, leading to death. The post-mortem examination revealed an enlarged heart with dilated ventricles and a markedly thickened endocardium. The cause of death was determined to be dilated cardiomyopathy caused by endocardial fibroelastosis. The study highlights the importance of gross specimen examination and special staining methods in determining the cause of death. [Extracted from the article]

A recent report from the Mayo Clinic discusses the evaluation and management of sudden death risk in patients with repaired tetralogy of Fallot, a congenital heart defect. While progress has been made in preventing sudden cardiac death in these patients, ventricular arrhythmia and sudden death remain significant causes of morbidity and mortality. The report highlights the importance of noninvasive risk stratification to identify patients who may benefit from interventions such as catheter ablation or cardioverter defibrillator implantation. The authors emphasize the need for a multidisciplinary approach to assess individual patients and discuss treatment options with them and their families. [Extracted from the article]

A new report discusses research on the cardiovascular toxicity associated with bispecific T-cell engagers (BTEs), a class of drugs used to treat hematological malignancies. The study conducted a large-scale post-marketing surveillance to identify safety signals that may have been missed in early clinical trials. The findings showed that cardiovascular adverse events (CVAEs) were not uncommon with BTEs and were more likely to be fatal compared to non-CVAEs. Heart failure and myocarditis were particularly concerning, and further investigation is needed to understand their mechanisms and develop optimal surveillance strategies and treatment options. [Extracted from the article]

New research from the SRM Institute of Science and Technology in Chennai, India focuses on the use of deep learning algorithms to analyze electrocardiogram (ECG) signals for the early detection of cardiac arrhythmia, which can lead to sudden death. The researchers propose a deep convolutional neural network (DCNN) implemented on a field-programmable gate array (FPGA) to classify ECG signals. The proposed methodology achieves high classification accuracy on two different databases and consumes low power. This research provides valuable insights into the potential of emerging technologies in the field of cardiology and cardiovascular health. [Extracted from the article]

A recent study conducted by the University of Mississippi Medical Center explores the relationship between sickle cell anemia and sudden death. The researchers found that sickle cell disease patients have a higher risk of sudden death, but the underlying causes are not fully understood. The study also revealed that sickle cell disease patients have a significant prolongation of the heart rate-corrected QT interval, which may contribute to ventricular tachycardia. The findings suggest that there are distinct factors contributing to QT prolongation in sickle cell disease patients compared to the general African American population. [Extracted from the article]

The first patient has been enrolled in the PROFID EHRA trial, which aims to personalize the prevention of sudden cardiac death after a heart attack. The trial is challenging the routine implantation of a defibrillator in myocardial infarction survivors with heart failure. The study will test whether drug treatment alone is not inferior to drug treatment plus an implantable cardioverter defibrillator (ICD) for preventing sudden death in heart attack survivors with heart failure and reduced pump function. The trial will recruit 3,595 patients from 13 countries and is expected to provide important new information on the use of ICDs in these patients. [Extracted from the article]

A report from Beijing Children's Hospital in China discusses a study on anomalous right coronary artery originating from the aorta (ARCA-L) in children. The study included nine pediatric patients diagnosed with ARCA-L between January 2017 and December 2019. The patients displayed various clinical manifestations, and one patient experienced sudden death. Genetic defects may be associated with the occurrence of the disease. The study highlights the importance of understanding the clinical manifestations and genetic factors related to ARCA-L in children. [Extracted from the article]

The patient management system of claim 31, wherein at least one of the first physiological data or the second physiological data comprises patient symptom data. The patient management system of claim 41, wherein at least one of the first physiological data or the second physiological data comprises patient symptom data. The patient management system of claim 44, wherein the patient symptom data comprises patient-reported symptoms, each patient-reported symptom identified by one of the first or second pluralities of patients via a user interface of one of the plurality of monitoring medical devices or the plurality of therapeutic medical devices. The patient management system of claim 34, wherein the patient symptom data comprises patient-reported symptoms, each patient-reported symptom identified by one of the first or second pluralities of patients via a user interface of one of the plurality of monitoring medical devices or the plurality of therapeutic medical devices. [Extracted from the article]

Keywords for this news article include: Rome, Italy, Europe, Cardiac Death, Cardiovascular Diseases and Conditions, Coronary Artery Disease, Health and Medicine, Heart Arrest, Heart Disease, Heart Disorders and Diseases, Ischemic Heart Disease, Myocardial Ischemia, Risk and Prevention, Sudden Death, Department of Cardiovascular Sciences. Rome, Italy, Europe, Cardiovascular Diseases and Conditions, Coronary Artery Disease, Health and Medicine, Heart Arrest, Heart Disease, Heart Disorders and Diseases, Ischemic Heart Disease, Myocardial Ischemia, Risk and Prevention, Sudden Death, Cardiac Death Keywords: Rome; Italy; Europe; Cardiac Death; Cardiovascular Diseases and Conditions; Coronary Artery Disease; Health and Medicine; Heart Arrest; Heart Disease; Heart Disorders and Diseases; Ischemic Heart Disease; Myocardial Ischemia; Risk and Prevention; Sudden Death EN Rome Italy Europe Cardiac Death Cardiovascular Diseases and Conditions Coronary Artery Disease Health and Medicine Heart Arrest Heart Disease Heart Disorders and Diseases Ischemic Heart Disease Myocardial Ischemia Risk and Prevention Sudden Death 429 429 1 10/30/23 20231031 NES 231031 2023 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- Data detailed on Heart Disorders and Diseases - Heart Disease have been presented. [Extracted from the article]

The news reporters obtained a quote from the research from Kyushu University, "However, the association between abnormal ECG findings and the risk of sudden death in hemodialysis patients is yet to be fully elucidated. Keywords: Fukuoka; Japan; Asia; Cardiac Death; Cardiovascular Diseases and Conditions; Dialysis; Health and Medicine; Heart Arrest; Heart Disorders and Diseases; Hemodialysis; Risk and Prevention; Sudden Death EN Fukuoka Japan Asia Cardiac Death Cardiovascular Diseases and Conditions Dialysis Health and Medicine Heart Arrest Heart Disorders and Diseases Hemodialysis Risk and Prevention Sudden Death 750 750 1 10/24/23 20231023 NES 231023 2023 OCT 23 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Research findings on Heart Disorders and Diseases - Heart Arrest are discussed in a new report. [Extracted from the article]

Keywords: Anakinra Therapy; Antirheumatics; Arrhythmia; Biomarkers; C-Reactive Protein; Cardiac Death; Cardiology; Cardiovascular Diseases and Conditions; Clinical Research; Clinical Trials and Studies; Diagnostics and Screening; Drugs and Therapies; Genetics; Health and Medicine; Heart Arrest; Heart Disease; Heart Disorders and Diseases; Heart Disorders and Diseases - Heart Arrest; Heart Failure; Left Ventricular Assist Device; Medical Devices; Pharmaceuticals; Proteomics; Risk and Prevention; Sudden Death; Ventricular Assist Device EN Anakinra Therapy Antirheumatics Arrhythmia Biomarkers C-Reactive Protein Cardiac Death Cardiology Cardiovascular Diseases and Conditions Clinical Research Clinical Trials and Studies Diagnostics and Screening Drugs and Therapies Genetics Health and Medicine Heart Arrest Heart Disease Heart Disorders and Diseases Heart Disorders and Diseases - Heart Arrest Heart Failure Left Ventricular Assist Device Medical Devices Pharmaceuticals Proteomics Risk and Prevention Sudden Death Ventricular Assist Device 1262 1262 1 10/16/23 20231020 NES 231020 2023 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Staff editors report on the newly launched clinical trial, NCT06062966, which has the following summary description: "End-stage heart failure (HF) is a progressive illness with a mortality rate similar to most advanced cancers. Roughly 5% of patients with HF have end-stage disease that is refractory to medical therapy (stage D heart failure). Roughly 5% of patients with HF have end-stage disease that is refractory to medical therapy (stage D heart failure). [Extracted from the article]

Cardiac Death, Cardiomyopathies, Cardiovascular Diseases and Conditions, Health and Medicine, Heart Arrest, Heart Disease, Heart Disorders and Diseases, Left Ventricular Dysfunction, Sudden Death, Takotsubo Cardiomyopathy Keywords: Cardiac Death; Cardiomyopathies; Cardiovascular Diseases and Conditions; Health and Medicine; Heart Arrest; Heart Disease; Heart Disorders and Diseases; Left Ventricular Dysfunction; Sudden Death; Takotsubo Cardiomyopathy EN Cardiac Death Cardiomyopathies Cardiovascular Diseases and Conditions Health and Medicine Heart Arrest Heart Disease Heart Disorders and Diseases Left Ventricular Dysfunction Sudden Death Takotsubo Cardiomyopathy 214 214 1 10/16/23 20231020 NES 231020 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Imaging Week -- Current study results on heart arrest have been published. [Extracted from the article]

Being implanted within the patient, the device continuously monitors the patient's heart for treatable arrhythmias and, when such an arrhythmia is detected, the device applies corrective electrical pulses directly to the heart. Keywords: Arrhythmia; Cardiac Arrhythmias; Cardiac Death; Cardio Device; Cardiology; Cardiovascular; Cardiovascular Diseases and Conditions; Health and Medicine; Heart Arrest; Heart Disease; Heart Disorders and Diseases; Heart Rate; Hemodynamics; Medical Devices; Patent Application; Risk and Prevention; Software; Sudden Death; Tachycardia; Ventricular Fibrillation; Ventricular Tachycardia EN Arrhythmia Cardiac Arrhythmias Cardiac Death Cardio Device Cardiology Cardiovascular Cardiovascular Diseases and Conditions Health and Medicine Heart Arrest Heart Disease Heart Disorders and Diseases Heart Rate Hemodynamics Medical Devices Patent Application Risk and Prevention Software Sudden Death Tachycardia Ventricular Fibrillation Ventricular Tachycardia 1121 1121 1 10/16/23 20231016 NES 231016 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- A patent application by the inventor Volpe, Shane (Saltsburg, PA, US), filed on May 24, 2023, was made available online on September 28, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. The one of the monitor and the remote server can be configured to delay the software update, cancel indefinitely the software update, or only partially carry out the software update based on the determination that the software update affects a critical function of the monitor. [Extracted from the article]

"Clause 24: The ambulatory medical device of any of clauses 1-23, wherein the monitoring and self-test circuitry is configured to classify the triggering event and, based on the classification, determine whether to initiate a self-test of the continuous-use medical device. "Clause 10: The ambulatory medical device of clauses 8 or 9, wherein the device configuration update comprises an update to one or more device parameters set in the ambulatory medical device. "Clause 6: The ambulatory medical device of any of clauses 1-5, further comprising at least one of a single axis accelerometer, a multi-axis accelerometer, and a piezoelectric transducer for detecting the at least one of the impact and the vibration event experienced by the ambulatory medical device. [Extracted from the article]

Brain Diseases and Conditions, Cardiac Death, Cardiovascular Diseases and Conditions, Central Nervous System Diseases and Conditions, Epilepsy, Genetics, Health and Medicine, Heart Arrest, Heart Disorders and Diseases, Nervous System Diseases and Conditions, Neurologic Manifestations, Risk and Prevention, Seizures, Sudden Death, University of Michigan Keywords: Brain Diseases and Conditions; Cardiac Death; Cardiovascular Diseases and Conditions; Central Nervous System Diseases and Conditions; Epilepsy; Genetics; Health and Medicine; Heart Arrest; Heart Disorders and Diseases; Nervous System Diseases and Conditions; Neurologic Manifestations; Risk and Prevention; Seizures; Sudden Death; University of Michigan EN Brain Diseases and Conditions Cardiac Death Cardiovascular Diseases and Conditions Central Nervous System Diseases and Conditions Epilepsy Genetics Health and Medicine Heart Arrest Heart Disorders and Diseases Nervous System Diseases and Conditions Neurologic Manifestations Risk and Prevention Seizures Sudden Death University of Michigan 1016 1016 1 10/09/23 20231009 NES 231009 2023 OCT 9 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Researchers at the University of Michigan have developed a model for studying one type of familial epilepsy, opening the door to understanding-and eventually targeting-the mechanisms that lead to the disorder and its associated fatalities. [Extracted from the article]

The work is also anticipated to evaluate the impact of mitral valve repair surgery on heart inflammation and on the recurrence of malignant arrhythmias after corrective surgery." Keywords: Arrhythmia; Cardiac Death; Cardiology; Cardiovascular; Cardiovascular Diseases and Conditions; Cardiovascular Research; Diagnostics and Screening; Engineering; Government Agencies Offices and Entities; Health and Medicine; Heart Arrest; Heart Disorders and Diseases; Heart Valves; Inflammation; Mitral Valve; Radiology; Risk and Prevention; Sudden Death; Surgery; Technology; The Mount Sinai Hospital / Mount Sinai School of Medicine EN Arrhythmia Cardiac Death Cardiology Cardiovascular Cardiovascular Diseases and Conditions Cardiovascular Research Diagnostics and Screening Engineering Government Agencies Offices and Entities Health and Medicine Heart Arrest Heart Disorders and Diseases Heart Valves Inflammation Mitral Valve Radiology Risk and Prevention Sudden Death Surgery Technology The Mount Sinai Hospital / Mount Sinai School of Medicine 328 328 1 10/09/23 20231009 NES 231009 2023 OCT 9 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- (New York, NY -) - Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $10.2 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to investigate risk factors for malignant arrhythmias in mitral valve prolapse. [Extracted from the article]

Keywords: Petah Tikva; Israel; Asia; Cardiac Death; Cardiovascular Diseases and Conditions; Defibrillators; Health and Medicine; Heart Arrest; Heart Disorders and Diseases; Medical Devices; Pediatrics; Risk and Prevention; Sudden Death EN Petah Tikva Israel Asia Cardiac Death Cardiovascular Diseases and Conditions Defibrillators Health and Medicine Heart Arrest Heart Disorders and Diseases Medical Devices Pediatrics Risk and Prevention Sudden Death 157 157 1 09/19/23 20230922 NES 230922 2023 SEP 23 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Sudden Death is the subject of a report. Keywords for this news article include: Asia, Israel, Pediatrics, Petah Tikva, Heart Arrest, Sudden Death, Cardiac Death, Defibrillators, Medical Devices, Health and Medicine, Risk and Prevention, Heart Disorders and Diseases, Cardiovascular Diseases and Conditions. [Extracted from the article]

Asia, Blood Vessels, Cardiac Death, Cardiovascular Diseases and Conditions, Cardiovascular System, Emerging Technologies, Health and Medicine, Heart Arrest, Heart Attack, Heart Disease, Heart Disorders and Diseases, Myocardial Infarction, Myocardial Ischemia, Nanotechnology, Nanovesicles, National Research Council of Science & Technology, Stem Cell Research, Sudden Death, Technology, Vascular Diseases and Conditions Keywords: Asia; Blood Vessels; Cardiac Death; Cardiovascular Diseases and Conditions; Cardiovascular System; Emerging Technologies; Health and Medicine; Heart Arrest; Heart Attack; Heart Disease; Heart Disorders and Diseases; Myocardial Infarction; Myocardial Ischemia; Nanotechnology; Nanovesicles; National Research Council of Science & Technology; Stem Cell Research; Sudden Death; Technology; Vascular Diseases and Conditions EN Asia Blood Vessels Cardiac Death Cardiovascular Diseases and Conditions Cardiovascular System Emerging Technologies Health and Medicine Heart Arrest Heart Attack Heart Disease Heart Disorders and Diseases Myocardial Infarction Myocardial Ischemia Nanotechnology Nanovesicles National Research Council of Science & Technology Stem Cell Research Sudden Death Technology Vascular Diseases and Conditions 483 483 1 09/11/23 20230911 NES 230911 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- Myocardial infarction, the number one cause of sudden death in adults and the number two cause of death in Korea, is a deadly disease with an initial mortality rate of 30%, and about 5-10% of patients die even if they are transported to a medical center for treatment. [Extracted from the article]

The PROFID EHRA trial will be the first randomised adequately powered assessment of the potential benefit of ICD therapy in myocardial infarction survivors with reduced LVEF under contemporary optimal medical therapy. Keywords: Cardiac Death; Cardiology; Cardiovascular Diseases and Conditions; Defibrillators; Drugs and Therapies; European Society of Cardiology; Genetics; Health and Medicine; Heart Arrest; Heart Attack; Heart Disease; Heart Disorders and Diseases; Heart Failure; Hospitals; Medical Devices; Myocardial Infarction; Myocardial Ischemia; Pharmaceuticals; Risk and Prevention; Sudden Cardiac Death; Sudden Death; Therapy; Vascular Diseases and Conditions EN Cardiac Death Cardiology Cardiovascular Diseases and Conditions Defibrillators Drugs and Therapies European Society of Cardiology Genetics Health and Medicine Heart Arrest Heart Attack Heart Disease Heart Disorders and Diseases Heart Failure Hospitals Medical Devices Myocardial Infarction Myocardial Ischemia Pharmaceuticals Risk and Prevention Sudden Cardiac Death Sudden Death Therapy Vascular Diseases and Conditions 1357 1357 1 09/11/23 20230911 NES 230911 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Amsterdam, Netherlands - 26 Aug 2023: Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial infarction survivors with heart failure still an adequate therapy for prevention of sudden cardiac death?. [Extracted from the article]

Cardiac Death, Cardiovascular Diseases and Conditions, Health and Medicine, Heart Arrest, Heart Disorders and Diseases, Heart Rate, Hemodynamics, Risk and Prevention, Sudden Death Keywords: Cardiac Death; Cardiovascular Diseases and Conditions; Health and Medicine; Heart Arrest; Heart Disorders and Diseases; Heart Rate; Hemodynamics; Risk and Prevention; Sudden Death EN Cardiac Death Cardiovascular Diseases and Conditions Health and Medicine Heart Arrest Heart Disorders and Diseases Heart Rate Hemodynamics Risk and Prevention Sudden Death 384 384 1 09/11/23 20230911 NES 230911 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Investigators publish new report on sudden death. [Extracted from the article]

We screened the complete exome sequence database of the Pediatrics Cardiac Genomics Consortium and identified a cohort with a de novo CHD4 (chromodomain helicase DNA-binding protein 4) proband, CHD4(M202I), with congenital heart defects. Keywords: Chapel Hill; State:North Carolina; United States; North and Central America; Cardiac Death; Cardiology; Cardiovascular Diseases and Conditions; Chromatin; Genetics; Health and Medicine; Heart Arrest; Heart Disorders and Diseases; Nucleoproteins; Proteins; Risk and Prevention; Sudden Death EN Chapel Hill State:North Carolina United States North and Central America Cardiac Death Cardiology Cardiovascular Diseases and Conditions Chromatin Genetics Health and Medicine Heart Arrest Heart Disorders and Diseases Nucleoproteins Proteins Risk and Prevention Sudden Death 820 820 1 08/28/23 20230828 NES 230828 2023 AUG 28 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Researchers detail new data in Sudden Death. [Extracted from the article]

Keywords: Arrhythmia; Cardiac Arrhythmias; Cardiac Death; Cardio Device; Cardiology; Cardiovascular; Cardiovascular Diseases and Conditions; Drugs and Therapies; Health and Medicine; Heart Arrest; Heart Disease; Heart Disorders and Diseases; Heart Failure; Heart Rate; Hemodynamics; Medical Devices; Patent Application; Risk and Prevention; Sudden Death; Tachycardia; Therapy; Ventricular Fibrillation EN Arrhythmia Cardiac Arrhythmias Cardiac Death Cardio Device Cardiology Cardiovascular Cardiovascular Diseases and Conditions Drugs and Therapies Health and Medicine Heart Arrest Heart Disease Heart Disorders and Diseases Heart Failure Heart Rate Hemodynamics Medical Devices Patent Application Risk and Prevention Sudden Death Tachycardia Therapy Ventricular Fibrillation 1111 1111 1 08/21/23 20230825 NES 230825 2023 AUG 21 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A patent application by the inventors Penkunas, Saundra L. (Portland, OR, US); Swenglish, Christopher Lawrence (Connellsville, PA, US), filed on January 23, 2023, was made available online on August 3, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. "When a patient is deemed at high risk of death from arrhythmias, such as ventricular fibrillation or ventricular tachycardia, electrical devices can be implanted so as to be readily available when treatment is needed. The wearable cardiac therapeutic device according to claim 61, wherein at least a portion of the opening(s) are aligned with respective electrically conductive fluid deployment opening(s) on the therapy electrode to facilitate transfer of the electrically conductive fluid from the at least one therapy electrode to the patient's skin via the opening(s). [Extracted from the article]